The Role of Pulmonary Metastasectomy in Breast Cancer with Limited Progression Following CDK4/6 Inhibitor Therapy: A Case Report

• DOI: 10.4103/ejcrp.ejcrp-d-24-00025
• Publication Date: 2024-12-06T10:00:28Z
• Authors: Yu-Ting Su; Shang-Hung Chen
• Keywords: Metastasectomy; Fulvestrant; Systemic therapy

Abstract Metastatic breast cancer is primarily managed with systemic therapy; however, the role of pulmonary metastasectomy (PM) in patients oligometastases remains uncertain. We present case a 56-year-old postmenopausal woman who developed lung and bone metastases 4 years after resection her primary tumor. Due to progression metastasis following combined therapy ribociclib fulvestrant for advanced disease, she underwent PM, which histologically confirmed metastasis. Following procedure, continued same achieved stable disease. This highlights that PM can aid accurate differential diagnosis nodules patients. For selected individuals, particularly those limited CDK4/6 inhibitor therapy, may be considered an additional treatment option.